Company profile for Theriva Biologics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Theriva Biologics is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Our therapies are designed to enable systemic delivery and have the potential to enhance current standard-of-care therapies, offering patients with difficult-to-treat cancers the chance of a longer life. Led by a team of experienced ...
Theriva Biologics is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Our therapies are designed to enable systemic delivery and have the potential to enhance current standard-of-care therapies, offering patients with difficult-to-treat cancers the chance of a longer life. Led by a team of experienced leaders with a vision for clinical innovation, we are committed to offering new therapeutic modalities that improve the way cancer is treated.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
9605 Medical Center Drive, Suite 270, Rockville, Maryland 20850
Telephone
Telephone
(301) 417-4364
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/12/3186207/0/en/Theriva-Biologics-Reports-Third-Quarter-2025-Operational-Highlights-and-Financial-Results.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/10/24/3173023/0/en/Theriva-Biologics-Provides-Response-to-Unusual-Market-Action.html

GLOBENEWSWIRE
24 Oct 2025

https://www.globenewswire.com/news-release/2025/10/16/3167886/0/en/Theriva-Biologics-Announces-a-Warrant-Inducement-Transaction-for-4-0-Million-in-Gross-Proceeds.html

GLOBENEWSWIRE
16 Oct 2025

https://www.globenewswire.com/news-release/2025/10/13/3165505/0/en/Theriva-Biologics-Announces-Upcoming-Presentations-at-Medical-Meetings.html

GLOBENEWSWIRE
13 Oct 2025

https://www.globenewswire.com/news-release/2025/10/06/3161648/0/en/Theriva-Biologics-Announces-Presentation-Describing-Next-Generation-Oncolytic-Adenovirus-VCN-12-at-the-32nd-Annual-Congress-of-the-European-Society-of-Gene-Cell-Therapy-ESGCT.html

GLOBENEWSWIRE
06 Oct 2025

https://www.globenewswire.com/news-release/2025/08/11/3130826/0/en/Theriva-Biologics-Reports-Second-Quarter-2025-Operational-Highlights-and-Financial-Results.html

GLOBENEWSWIRE
11 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty